RU2016152226A - Фармацевтический состав для уменьшения частоты мочеиспускания и способ его применения - Google Patents
Фармацевтический состав для уменьшения частоты мочеиспускания и способ его применения Download PDFInfo
- Publication number
- RU2016152226A RU2016152226A RU2016152226A RU2016152226A RU2016152226A RU 2016152226 A RU2016152226 A RU 2016152226A RU 2016152226 A RU2016152226 A RU 2016152226A RU 2016152226 A RU2016152226 A RU 2016152226A RU 2016152226 A RU2016152226 A RU 2016152226A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- prostaglandin
- inhibitor
- specified
- urination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2014/041378 WO2015187183A1 (en) | 2014-06-06 | 2014-06-06 | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016152226A3 RU2016152226A3 (enExample) | 2018-07-09 |
| RU2016152226A true RU2016152226A (ru) | 2018-07-09 |
Family
ID=54767122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016152226A RU2016152226A (ru) | 2014-06-06 | 2014-06-06 | Фармацевтический состав для уменьшения частоты мочеиспускания и способ его применения |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3151834A4 (enExample) |
| JP (1) | JP2017516832A (enExample) |
| KR (1) | KR20170010440A (enExample) |
| CN (1) | CN106714805A (enExample) |
| AU (1) | AU2014396189A1 (enExample) |
| MX (1) | MX2016016039A (enExample) |
| RU (1) | RU2016152226A (enExample) |
| SG (1) | SG11201610383YA (enExample) |
| WO (1) | WO2015187183A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9532959B2 (en) | 2010-07-08 | 2017-01-03 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
| US10105328B2 (en) | 2014-06-06 | 2018-10-23 | Wellesley Pharmaceuticals, Llc | Composition for reducing frequency of urination, method of making and use thereof |
| WO2017106032A1 (en) * | 2015-12-18 | 2017-06-22 | Wellesley Pharmaceuticals, Llc | Composition for reducing frequency of urination, method of making and use thereof |
| JP2019031556A (ja) * | 2018-10-31 | 2019-02-28 | ウェルズリー ファーマスーティカルズ、エルエルシー | 排尿頻度を減少させるための医薬製剤およびその使用の方法 |
| WO2021154974A1 (en) * | 2020-01-30 | 2021-08-05 | The Regents Of The University Of California | Screening for inhibitors of prostaglandin e synthase 3 useful for treatment of prostate cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010029519A (ko) * | 1996-09-19 | 2001-04-06 | 이곤 이 버그 | 요실금 치료 방법 |
| EP1447096A1 (en) * | 2001-11-19 | 2004-08-18 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary frequency |
| JP2005526040A (ja) * | 2002-02-19 | 2005-09-02 | ファルマシア・コーポレーション | 失禁の治療のためのシクロオキシゲナーゼ阻害剤及び抗ムスカリン剤の使用 |
| EP1879578A4 (en) * | 2005-03-21 | 2009-05-13 | Dov Pharmaceutical Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE |
| KR20190049928A (ko) * | 2012-01-04 | 2019-05-09 | 웰즐리 파마슈티컬스 엘엘씨 | 배뇨 빈도를 감소시키기 위한 서방형 제제 및 이의 사용 방법 |
| MX2014008283A (es) * | 2012-01-04 | 2015-03-03 | Wellesley Pharmaceutical Llc | Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta. |
| WO2013142197A1 (en) * | 2012-03-19 | 2013-09-26 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
-
2014
- 2014-06-06 CN CN201480081004.5A patent/CN106714805A/zh active Pending
- 2014-06-06 RU RU2016152226A patent/RU2016152226A/ru not_active Application Discontinuation
- 2014-06-06 WO PCT/US2014/041378 patent/WO2015187183A1/en not_active Ceased
- 2014-06-06 MX MX2016016039A patent/MX2016016039A/es unknown
- 2014-06-06 JP JP2016571196A patent/JP2017516832A/ja active Pending
- 2014-06-06 SG SG11201610383YA patent/SG11201610383YA/en unknown
- 2014-06-06 EP EP14894044.8A patent/EP3151834A4/en not_active Ceased
- 2014-06-06 KR KR1020177000237A patent/KR20170010440A/ko not_active Ceased
- 2014-06-06 AU AU2014396189A patent/AU2014396189A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017516832A (ja) | 2017-06-22 |
| CN106714805A (zh) | 2017-05-24 |
| WO2015187183A1 (en) | 2015-12-10 |
| KR20170010440A (ko) | 2017-01-31 |
| SG11201610383YA (en) | 2017-02-27 |
| EP3151834A1 (en) | 2017-04-12 |
| AU2014396189A1 (en) | 2016-12-22 |
| RU2016152226A3 (enExample) | 2018-07-09 |
| EP3151834A4 (en) | 2018-01-03 |
| MX2016016039A (es) | 2017-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016152226A (ru) | Фармацевтический состав для уменьшения частоты мочеиспускания и способ его применения | |
| RU2014142066A (ru) | Состав с длительным высвобождением для снижения частоты мочеиспускания и способ его применения | |
| PE20140960A1 (es) | Formulaciones que comprenden un inhibidor de dpp4 | |
| WO2012079092A3 (en) | Testosterone undecanoate compositions | |
| WO2009017838A3 (en) | Combinations of jak-2 inhibitors and other agents | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| HRP20191617T1 (hr) | Kombinacija koja sadrži inhibitor mek i inhibitor b-raf | |
| NZ619076A (en) | Isoxazolines as inhibitors of fatty acid amide hydrolase | |
| JP2009541443A5 (enExample) | ||
| UA115139C2 (uk) | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту | |
| FI3838271T3 (fi) | Kohonneiden eosinofiilien ja/tai basofiilien pitoisuuksien hoito | |
| JP2015510928A5 (enExample) | ||
| RU2014131238A (ru) | Состав с отсроченным высвобождением для уменьшения частоты мочеиспускания и способ его применения | |
| ECSP11011453A (es) | Tratamiento de trastornos cognitivos con determinados receptores de ácido nicotínico alfa-7 en combinación con inhibidores de acetilcolinesterasa | |
| MY173582A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
| HRP20171743T1 (hr) | Sastavi i postupci za savladavanje otpornosti na tramadol | |
| MX351059B (es) | Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion. | |
| AR078951A1 (es) | Esferoides de farmacos revestidos y usos de los mismos para la eliminacion o reduccion de afecciones tales como emesis y diarrea | |
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| AR073435A1 (es) | Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine | |
| EP4599894A3 (en) | Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor | |
| JP2017516832A5 (enExample) | ||
| MX2014002480A (es) | Uso del compuesto organico para el tratamiento del sindrome de noonan. | |
| RU2015106672A (ru) | Фармацевтическая композиция для уменьшения частоты мочеиспускания и способ ее применения | |
| JP2015522659A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200116 |